SCHEMBL10162477

SCHEMBL10162477

CC(=O)c1ccc(CNC(=O)c2cc(C(=O)NCc3cccc(C(F)(F)F)c3)nc3ccnn23)cc1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 2/20 0.50
KMT2A Q03164 2/20 0.50
MLYCD O95822 1/20 0.48
MMP13 P45452 3/20 0.48
KCNN3 Q9UGI6 1/20 0.48
HRH4 Q9H3N8 1/20 0.47
PLA2G1B P04054 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
GAA P10253 1/20 0.45
CYP2D6 P10635 1/20 0.45
CYP2C19 P33261 1/20 0.45
TDP1 Q9NUW8 1/20 0.45
ATG4B Q9Y4P1 1/20 0.45
MAOB P27338 1/20 0.45
DHFR P00374 1/20 0.45
MAPK14 Q16539 1/20 0.45
NAMPT P43490 1/20 0.44
PTGER4 P35408 2/20 0.44
ALPL P05186 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10162436 0.91 MMP13 (0.46) MEN1KMT2AMLYCDMMP13KCNN3
SCHEMBL10162474 0.87 ROCK2 (0.52) KCNN3MAPK14NAMPT
SCHEMBL10162483 0.85 POLB (0.47) MMP13LMNA
SCHEMBL10162468 0.84 ROCK2 (0.44) MMP13KCNN3CYP3A4CYP2D6
SCHEMBL10162460 0.84 MMP13 (0.45) MMP13MAOBPTGER4
SCHEMBL10162464 0.83 MMP13 (0.53) MMP13MAPK14
SCHEMBL10162181 0.82 HRH4 (0.44) MEN1KMT2AMLYCDMMP13KCNN3
SCHEMBL10162467 0.82 MAPK1 (0.43) MMP13CYP1A2CYP2C19PTGER4LMNA
SCHEMBL10162432 0.78 RIPK1 (0.48) MMP13KCNN3MAPK14
SCHEMBL10161633 0.78 MMP13 (0.61) MEN1KMT2AMMP13KCNN3HRH4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8835441-B2 Heterobicyclic metalloprotease inhibitors AMGEN INC. (US) 2014-09-16 US disclosed
US-20120015920-A1 HETEROBICYCLIC METALLOPROTEASE INHIBITORS ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2012-01-19 US disclosed
US-7795245-B2 Heterobicyclic metalloprotease inhibitors Atlantos Pharmaceuticals Holding, Inc. (US) 2010-09-14 US disclosed
US-20090312312-A1 Heterobicyclic Metalloprotease Inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. (US) 2009-12-17 US disclosed
US-20090137547-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS HOLDING, INC. 2009-05-28 US disclosed
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors ALANTOS PHARMACEUTICALS, INC. 2007-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090312312-A1 Heterobicyclic Metalloprotease Inhibitors MMP13, TIMP3, MMP3 MEN1 3090/4885KMT2A 3548/4885MLYCD 1621/4885
US-20120015920-A1 HETEROBICYCLIC METALLOPROTEASE INHIBITORS MMP13, TIMP3, MMP3 MEN1 3090/4885KMT2A 3548/4885MLYCD 1621/4885
US-20090137547-A1 Heterobicyclic metalloprotease inhibitors MMP13, TIMP3, MMP3 MEN1 3090/4885KMT2A 3548/4885MLYCD 1621/4885
US-20070155738-A1 Heterobicyclic metalloprotease inhibitors MMP13, TIMP3, MMP3 MEN1 3090/4885KMT2A 3548/4885MLYCD 1621/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.